Heart Test Laboratories Inc (HSCS) Stock Price, Quote & News

Company Profile

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG info...

Industry: Medical Devices

Sector: Healthcare

Phone: 682-237-7781

Website: heartsciences.com

Address:

550 Reserve Street, Suite 360, Southlake, United States

doctortampa Jul. 6 at 4:54 AM

$HSCS For those unaware, there is a current offering for preferred shares BUT there is NO ATM ACTIVE! $HSCS is raising money that they say will fund operations until commercialization.

0 · Reply

SugarPumping Jul. 5 at 10:50 AM

$HSCS looks they need offering soon keep it in mind 🤞

1 · Reply

14745Barclay Jul. 3 at 3:37 PM

$HSCS The fact that this company still can’t even the FDA submission in is mind boggling. Is this company like Therano?

1 · Reply

doctortampa Jul. 1 at 3:31 AM

$HSCS cost to borrow rate dipped but is back to increasing with around only 30,000 shares to borrow for shorting 🤑🤑

0 · Reply

doctortampa Jun. 27 at 5:17 AM

$HSCS cost to borrow is not going down, only up. only 25,000 shares to short with. hard to borrow.

0 · Reply

doctortampa Jun. 26 at 2:11 PM

$HSCS cost to borrow continues to rise...

0 · Reply

Bullchips Jun. 25 at 4:01 AM

$HSCS Is this a good deal? Or should I just buy the stock? This was a ad in Stocktwits newsletter yesterday. While HeartSciences is already public, they’re giving investors an opportunity not available on the public exchange: $3.50 units that include 1 share of convertible preferred stock + 1 warrant. Together, it all amounts to 500% 1-year target upside based on analyst projections. Learn more and invest in HeartSciences today.

0 · Reply

doctortampa Jun. 25 at 12:33 AM

$HSCS well that escalated quickly. Also very few shares left to borrow to short with. Dip down to 9,000 this morning before going back up to 20,000 Could get interesting this week...

0 · Reply

doctortampa Jun. 24 at 12:06 AM

$HSCS Nice volume today, nice pop up to $4.30, and there's hardly any shares left to borrow to short with. This could get interesting

0 · Reply

doctortampa Jun. 18 at 8:13 PM

$HSCS also looks like it's getting extremely hard to borrow but very few shares left. My tits are currently jacked 🫡🫡

0 · Reply

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Jun 3, 2025, 9:00 AM EDT - 4 weeks ago

Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value

May 29, 2025, 9:00 AM EDT - 5 weeks ago

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

May 20, 2025, 9:00 AM EDT - 6 weeks ago

HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

May 8, 2025, 9:00 AM EDT - 2 months ago

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

May 7, 2025, 9:00 AM EDT - 2 months ago

HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

May 1, 2025, 9:00 AM EDT - 2 months ago

HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

Mar 13, 2025, 4:15 PM EDT - 4 months ago

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

Mar 10, 2025, 9:00 AM EDT - 4 months ago

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

Dec 16, 2024, 4:15 PM EST - 7 months ago

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

Nov 13, 2024, 9:00 AM EST - 8 months ago

HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Oct 14, 2024, 4:15 PM EDT - 9 months ago

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 12, 2024, 4:15 PM EDT - 10 months ago

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

Sep 12, 2024, 9:00 AM EDT - 10 months ago

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

Jul 29, 2024, 4:05 PM EDT - 1 year ago

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Jul 26, 2024, 9:00 AM EDT - 1 year ago

Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

Jul 25, 2024, 8:30 AM EDT - 1 year ago

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

Jul 11, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Jun 4, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Regains Compliance with Nasdaq Listing Requirements

May 20, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

Apr 24, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Apr 2, 2024, 4:15 PM EDT - 1 year ago

HeartSciences to Present at the LD Micro Invitational XIV Conference

Mar 26, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Mar 14, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Mar 12, 2024, 9:00 AM EDT - 1 year ago

HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Mar 6, 2024, 9:00 AM EST - 1 year ago

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

Feb 26, 2024, 9:00 AM EST - 1 year ago

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Feb 12, 2024, 9:00 AM EST - 1 year ago

HeartSciences Expands its Scientific Advisory Board

Feb 1, 2024, 9:00 AM EST - 1 year ago

HeartSciences Appoints New Scientific Advisory Board Member

Jan 18, 2024, 8:00 AM EST - 1 year ago

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

Jan 3, 2024, 4:15 PM EST - 1 year ago

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

Dec 14, 2023, 4:15 PM EST - 1 year ago

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

Dec 5, 2023, 8:00 AM EST - 1 year ago

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

Nov 13, 2023, 8:45 AM EST - 1 year ago

HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Nov 3, 2023, 8:28 AM EDT - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

ARQT SINT

Sep 14, 2023, 4:15 PM EDT - 1 year ago

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

Sep 12, 2023, 4:15 PM EDT - 1 year ago

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

Sep 11, 2023, 4:15 PM EDT - 1 year ago

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

Sep 7, 2023, 9:00 AM EDT - 1 year ago

HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India

Aug 31, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

Aug 24, 2023, 9:00 AM EDT - 2 years ago

HeartSciences' MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

Aug 17, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

Jul 27, 2023, 9:00 AM EDT - 2 years ago

MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark

Jul 19, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

May 17, 2023, 8:00 AM EDT - 2 years ago

HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine

May 9, 2023, 8:15 AM EDT - 2 years ago

HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

May 8, 2023, 8:15 AM EDT - 2 years ago

HeartSciences to Participate at the Inaugural EF Hutton Global Conference

May 2, 2023, 8:15 AM EDT - 2 years ago

HeartSciences to Participate in The Benchmark Company's Virtual Individual Investor Healthcare Conference

Apr 17, 2023, 8:15 AM EDT - 2 years ago

HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023

Mar 16, 2023, 4:15 PM EDT - 2 years ago

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results

doctortampa Jul. 6 at 4:54 AM

$HSCS For those unaware, there is a current offering for preferred shares BUT there is NO ATM ACTIVE! $HSCS is raising money that they say will fund operations until commercialization.

0 · Reply

SugarPumping Jul. 5 at 10:50 AM

$HSCS looks they need offering soon keep it in mind 🤞

1 · Reply

14745Barclay Jul. 3 at 3:37 PM

$HSCS The fact that this company still can’t even the FDA submission in is mind boggling. Is this company like Therano?

1 · Reply

doctortampa Jul. 1 at 3:31 AM

$HSCS cost to borrow rate dipped but is back to increasing with around only 30,000 shares to borrow for shorting 🤑🤑

0 · Reply

doctortampa Jun. 27 at 5:17 AM

$HSCS cost to borrow is not going down, only up. only 25,000 shares to short with. hard to borrow.

0 · Reply

doctortampa Jun. 26 at 2:11 PM

$HSCS cost to borrow continues to rise...

0 · Reply

Bullchips Jun. 25 at 4:01 AM

0 · Reply

doctortampa Jun. 25 at 12:33 AM

$HSCS well that escalated quickly. Also very few shares left to borrow to short with. Dip down to 9,000 this morning before going back up to 20,000 Could get interesting this week...

0 · Reply

doctortampa Jun. 24 at 12:06 AM

$HSCS Nice volume today, nice pop up to $4.30, and there's hardly any shares left to borrow to short with. This could get interesting

0 · Reply

doctortampa Jun. 18 at 8:13 PM

$HSCS also looks like it's getting extremely hard to borrow but very few shares left. My tits are currently jacked 🫡🫡

0 · Reply

doctortampa Jun. 18 at 8:12 PM

$HSCS $HEARTSCIENCES Inc level two also got some nice buy walls

0 · Reply

doctortampa Jun. 18 at 8:11 PM

$HSCS $HEARTSCIENCES Inc damn look at them by walls after hours no less 👀👀

0 · Reply

alijane2013 Jun. 18 at 2:00 PM

$HSCS Looking good am adding

0 · Reply

Stocklife978 Jun. 18 at 1:30 PM

$HSCS 🚀

0 · Reply

doctortampa Jun. 18 at 4:23 AM

$HSCS hummmmm she's looking like she's shaping up nicely 🫡🫡🫡

0 · Reply

doctortampa Jun. 12 at 1:23 AM

$HSCS I agree 🤑🫡

0 · Reply

doctortampa Jun. 10 at 1:50 PM

$HSCS looks like its "Hard To Borrow" again. I think if I buy more shares, it will become even more hard...to borrow :P

1 · Reply

doctortampa Jun. 10 at 3:57 AM

$HSCS I'm back babyyyyyyyyyyy lol this website is full of snitches! LFG FDA submission 1H 2025!!!

0 · Reply

14745Barclay Jun. 9 at 4:46 PM

$HSCS this junk will slow bleed to sub $3 and I will load more. Rinse and repeat.

0 · Reply

Stocklife978 Jun. 9 at 1:28 PM

$HSCS

0 · Reply

ChefCurryStocks Jun. 6 at 10:47 PM

$HSCS Reload anything at $3 or lower

0 · Reply

JerrieGauze Jun. 6 at 9:37 PM

$HSCS benjamin sigh if very youre so bushish, why didn’t you invest in their Ponzi scheme soif this company does not have anything definitive as far as a positive FDA decision by end of August the company is gone and dissolved or bought …out just read their Edgar filings so in a sense you are gambling, and or a paid pumper they deserve what happens to them the stock is worth 1.70 or less until “approval “b4 compliance day in sept btw the patents are worthless in dissolution wake up

0 · Reply

Market Cap	2.27M
Revenue (ttm)	20,000.00
Net Income (ttm)	-6.61M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	11,938
Avg Vol	455,542
Day's Range	N/A - N/A
Shares Out	656,000.00
Stochastic %K	24%
Beta	3.16
Analysts	Strong Sell
Price Target	$13.50